XSpray strengthens patent portfolio for breakthrough particle production technology
(Thomson Reuters ONE) -
Stockholm, Sweden - November 04, 2010. XSpray Microparticles today announced
that the US Patent and Trademark Office has granted a patent relating to the
company's particle production technology. XSpray's RightSize(TM) Particle
technology provides complete control over particle production, enhancing drug
formulation options and optimizing the performance of challenging drug
substances, such as poorly soluble compounds, inhaled compounds, and
biomolecules.
The technology uses supercritical fluid (SCF) as an antisolvent for controlled
precipitation of an active pharmaceutical ingredient/drug substance. The new
patent approval covers both design and method patents relating to XSpray's
unique nozzle head, where precipitation of the drug substance takes place.
The breakthrough design enables reproducible production of small particles of
specific sizes, required for the development of inhalable drugs. It also enables
nanoparticles to be produced with a consistent particle size below 200 nm. The
technology is compatible with a wide range of excipients. These can, for
example, be added to increase stability and/or wettability in amounts from >50%
down to trace amounts.
The dimensions of the actual fluid mixing and spray forming regions are kept
constant at all scales. This means the technology can be effectively scaled up
to drug manufacturing volumes. Consistent high-quality particles are produced,
with full control over particle size, size distribution and polymorph,
irrespective of production scale.
XSpray's CEO, Per Andersson, commented, "RightSize Particle production offers
significant advantages over traditional micronization technology. It provides an
easy-to-operate, single-step process that gives the user full control over
particle properties. As well as being used for developing new chemical entities,
it is also ideally suited to drug reformulation and life cycle management."
"As a fully scalable SCF-based technology, RightSize Particle production
represents a significant breakthrough in drug particle manufacturing. Today, we
already offer GMP production of clinical trial materials to support our growing
customer base. As such, the patent is an important step that further strengthens
the company's intellectual property rights in the US," added Dr. Andersson.
For more information, contact:
Per Andersson, CEO, XSpray Microparticles AB
Tel: +46 (0)8 730 37 00
Email:per.andersson(at)xspray.com
About XSpray
XSpray Microparticles AB is a Swedish life science technology company with in-
depth knowledge of supercritical fluid technology, solid state properties,
formulation science and the drug development process. The Company's cutting-edge
platform technology - RightSize(TM) Particle manufacturing - uses supercritical
fluid as an antisolvent for controlled precipitation of an active pharmaceutical
ingredient/drug substance. The technology not only provides a superior process
to traditional methods but also delivers better quality pharmaceutical
particles, from discovery to production.
The process yields consistent powder particles in terms of size, shape and
morphology that simplify formulation and can be incorporated into a variety of
dosage forms, such as tablets, capsules and inhalation systems. RightSize
Particle technology addresses unmet therapeutic needs by enabling the
development of drugs with enhanced delivery options, such as faster onset of
action, and by adding innovative properties that truly benefit patients.
A key advantage of RightSize Particle technology is that it can be effectively
scaled up to production volumes, making it an important breakthrough in the
manufacture of pharmaceutical particles.
XSpray Microparticles has its headquarters and development laboratories in
Stockholm, Sweden, and offers GMP production at a state-of-the-art manufacturing
facility in Malmö, Sweden. Find out more at: www.xspray.com
[HUG#1458870]
XSpray strengthens patent portfolio for breakthrough particle production technology:
http://hugin.info/144419/R/1458870/398413.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: XSpray Microparticles AB via Thomson Reuters ONE
Datum: 04.11.2010 - 10:00 Uhr
Sprache: Deutsch
News-ID 48425
Anzahl Zeichen: 5085
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 163 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"XSpray strengthens patent portfolio for breakthrough particle production technology"
steht unter der journalistisch-redaktionellen Verantwortung von
XSpray Microparticles AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
